Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00744211 · ClinicalTrials.gov registry record · NA
Proteolytic Enzyme Induction Within the Human Myocardial Interstitium
A NA study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT00744211: Completed NA study, sponsored by VA Office of Research and Development.
NCT00744211 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00744211, a NA study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
A robust release of endothelin-1-1 (ET) with subsequent ETA subtype receptor (ET-AR) activation occurs in patients following cardiac surgery requiring cardiopulmonary bypass (CPB). Increased ET-AR activation has been identified in patients with poor left ventricular (LV) function (reduced ejection fraction; EF). Accordingly, this study tested the hypothesis that a selective ET-AR antagonist (ET-ARA) administered peri-operatively would favorably affect post-CPB hemodynamic profiles in patients with a pre-existing poor LVEF.
Interventions
- OTHER Vehicle
- DRUG 1mg/kg sitaxsentan sodium
- DRUG 2mg/kg sitaxsentan sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00744211
The ClinicalTrials.gov registry entry for NCT00744211 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle is the first listed.
NCT00744211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00744211 about?
NCT00744211 is a clinical study titled "Proteolytic Enzyme Induction Within the Human Myocardial Interstitium". A robust release of endothelin-1-1 (ET) with subsequent ETA subtype receptor (ET-AR) activation occurs in patients following cardiac surgery requiring cardiopulmonary bypass (CPB). Increased ET-AR activation has been identified in patients with poor left ventricular (LV) function (reduced ejection f...
What is the current status of trial NCT00744211?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2008-07. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00744211?
The interventions under investigation include: Vehicle (OTHER), 1mg/kg sitaxsentan sodium (DRUG), 2mg/kg sitaxsentan sodium (DRUG).
Who is sponsoring clinical trial NCT00744211?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.